Daunorubicin cardiotoxicity in childhood cancer [7]

Lancet

Volumn 352, Issue 9134, 1998, Pages 1150-

  Samuel, L ^a   Cummings, J ^a   Shaw, P ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN;

AREA UNDER THE CURVE; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; DRUG INFUSION; DRUG METABOLISM; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL;

EID: 0032480583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79797-X     Document Type: Letter

References (5)

1. S Hitchcock-Bryan R Gelber JR Cassady S Sallan The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukaemia Med Paed Oncol 14 1986 211 215
2. LJ Steinherz RG Steinherz CT Tan G Heller ML Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672 1677
3. J Shapira M Gotfried M Lishner M Raviel Reduced cardiotoxicity of doxorubicin by a 6 hour infusional regimen: a prospective randomised evaluation Cancer 65 1990 870 873
4. J Robert L Gianni Pharmacokinetics and metabolism of anthracyclines Cancer Surv 17 1993 219 252
5. de Jong J Schoofs PR Snabilie AM Best A van der Vijgh WJF The role of biotransformation in anthracycline-induced cardiotoxicity in mice J Pharm Exp Ther 266 1993 1312 1320